Status:
COMPLETED
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Lead Sponsor:
Pfizer
Conditions:
Carcinoma, Renal Cell
Eligibility:
All Genders
Brief Summary
The objective of this surveillance is to collect information about 1) adverse drug reaction not expected from the LPD (unknown adverse drug reaction), 2) the incidence of adverse drug reactions in thi...
Detailed Description
All the patients whom an investigator prescribes the first sunitinib malate(Sutent) should be registered.
Eligibility Criteria
Inclusion
- Patients need to be administered sunitinib malate (Sutent) in order to be enrolled in the surveillance.
Exclusion
- Patients not administered sunitinib malate (Sutent).
Key Trial Info
Start Date :
June 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 1 2015
Estimated Enrollment :
1674 Patients enrolled
Trial Details
Trial ID
NCT00716625
Start Date
June 1 2008
End Date
October 1 2015
Last Update
May 3 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.